- Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC
- Marks second approval under Eisai-Merck global collaboration to co-develop and co-commercialize LENVIMA, following Japan in March 2018
PR Newswire
WOODCLIFF LAKE, N.J. and KENILWORTH, N.J., Aug. 16, 2018